Many manufacturers offer programs that will reduce your out-of-pocket costs for this prescription. These programs are free but may have some rules or restrictions, so you’ll want to review carefully. When you’re ready to use this coupon, simply present the coupon to your pharmacist with a valid prescription for your medication.
|Program Name:||Kuvan 30 Day Free Trial|
|How do I get the discount?||Register online, and an enrollment counselor will contact you to complete your enrollment.|
|How much can I save?||You can receive a 30 day supply at no cost to you.|
|Do I need insurance?||No. This offer is the same with or without commercial insurance.|
|Number of uses:||Limit one per person.|
|Other notes:||You will need to work with a participating clinic, and be evaluated before the end of the trial period to see if you should continue taking Kuvan.|
Many programs are available from federal and state governments, non-profits, manufacturers, and other organizations to help you get the drugs you need at a reduced cost. Eligibility is often based on income, insurance or Medicare status, and other factors. You’ll need to apply through each program, either online, over the phone, or with your doctor's help. The following program is offered by the manufacturer of this drug.
|Program Name:||BioMarin Patient Assistance Program|
|How do I apply?||Contact a BPPS case manager at 1-866-906-6100 or firstname.lastname@example.org.|
|What are the benefits?||Contact a case manager to see how they can financially assit you.|
|What are the restrictions?||Most people without insurance and with limited incomes will qualify. You will need a valid prescription and proof of househould income.|
|Keep in mind||N/A|
It is possible that Kuvan may become available as generic sapropterin after November 2025. Generics are typically much cheaper than the branded version of a drug.
This is the earliest possible generic release date based on patent expiration at this time. It is possible that sapropterin could become available sooner or later, depending on FDA approval, other patents, and whether any manufacturers decide to make a generic version of Kuvan.